Javascript must be enabled to continue!
CGRPβ suppresses the pathogenesis of ulcerative colitis via the immunoproteasome
View through CrossRef
Abstract
Various factors have been implicated in the pathogenesis of ulcerative colitis (UC), with immune system failure being the most important one. Calcitonin gene-related peptide (CGRP), a neuropeptide with two isoforms, CGRPα and CGRPβ, has been reported to regulate the immune system. In this study, we investigated the role of CGRP isoforms in UC pathogenesis. We induced UC-like symptoms in CGRPα and CGRPβ knockout (KO) mice using dextran sulphate sodium. Compared to wild-type and CGRPα KO mice, CGRPβ-deficient mice exhibited severe symptoms with increased blood in the stool and diarrhoea. Proteome analysis revealed significant up-regulation of immune-related proteins and immunoproteasome components in CGRPβ-deficient mice, suggesting that an enhanced immune response contributes to the severity of this disease. Treatment with ONX-0914, an immunoproteasome inhibitor, markedly improved these symptoms, highlighting the role of the immunoproteasome in exacerbating UC. This study provides the first evidence that CGRPβ protects against UC by modulating immune responses, particularly those mediated by the immunoproteasome. Our findings suggest that functional differences in CGRP isoforms may influence the severity and management of UC. This insight into the neuro-immune mechanism of UC opens avenues for novel therapies that address both the neural and immune aspects of this disease.
Springer Science and Business Media LLC
Title: CGRPβ suppresses the pathogenesis of ulcerative colitis via the immunoproteasome
Description:
Abstract
Various factors have been implicated in the pathogenesis of ulcerative colitis (UC), with immune system failure being the most important one.
Calcitonin gene-related peptide (CGRP), a neuropeptide with two isoforms, CGRPα and CGRPβ, has been reported to regulate the immune system.
In this study, we investigated the role of CGRP isoforms in UC pathogenesis.
We induced UC-like symptoms in CGRPα and CGRPβ knockout (KO) mice using dextran sulphate sodium.
Compared to wild-type and CGRPα KO mice, CGRPβ-deficient mice exhibited severe symptoms with increased blood in the stool and diarrhoea.
Proteome analysis revealed significant up-regulation of immune-related proteins and immunoproteasome components in CGRPβ-deficient mice, suggesting that an enhanced immune response contributes to the severity of this disease.
Treatment with ONX-0914, an immunoproteasome inhibitor, markedly improved these symptoms, highlighting the role of the immunoproteasome in exacerbating UC.
This study provides the first evidence that CGRPβ protects against UC by modulating immune responses, particularly those mediated by the immunoproteasome.
Our findings suggest that functional differences in CGRP isoforms may influence the severity and management of UC.
This insight into the neuro-immune mechanism of UC opens avenues for novel therapies that address both the neural and immune aspects of this disease.
Related Results
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Anti-Tumor Activity of Immunoproteasome Selective Inhibitors.
Abstract
Background: The immunoproteasome is a form of the proteasome that is distinct from the broadly expressed constitutive proteasome. The immunoproteasome, whic...
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Osteopathic Primary Care Treatment Options for Ulcerative Colitis
Ulcerative colitis is a multifactorial, chronic inflammatory disease of the bowel that can cause physical, social and emotional injury to the patient. While perhaps not always maki...
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Comparison of PUCAI Score in Mesalazine-Treated Children with Ulcerative Colitis
Background: Ulcerative colitis is a chronic idiopathic inflammatory bowel disease (IBD) characterized by intestinal inflammation confined to the superficial mucosal layer. Mesalazi...
Pharmacological correction of ulcerative colitis with dalargin
Pharmacological correction of ulcerative colitis with dalargin
Introduction: Ulcerative colitis is a chronic colonic disease with frequent relapses, affecting mainly people of active age. The effectiveness of existing treatment methods remains...
Traditional Chinese medicine treatment of ulcerative colitis
Traditional Chinese medicine treatment of ulcerative colitis
This paper discusses the treatment of ulcerative colitis with Traditional Chinese Medicine, and expounds the specific pathogenesis of ulcerative colitis. In addition, we put forwar...
In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis
In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis
AbstractGiven the complex nature of ulcerative colitis, combination therapy targeting multiple pathogenic genes and pathways of ulcerative colitis may be required. Unfortunately, c...
Deep Learning Algorithm for Diagnose Endoscopic and Histological Images With Ulcerative Colitis
Deep Learning Algorithm for Diagnose Endoscopic and Histological Images With Ulcerative Colitis
Abstract
The goal of treatment for ulcerative colitis is to achieve histological and endoscopic remission. Aiming at the problem that the observer will be affected by subje...
ETRASIMOD IN THE TREATMENT OF ULCERATIVE COLITIS: EFFICACY, SAFETY, AND ITS ROLE IN THERAPY - REVIEW
ETRASIMOD IN THE TREATMENT OF ULCERATIVE COLITIS: EFFICACY, SAFETY, AND ITS ROLE IN THERAPY - REVIEW
Ulcerative colitis (UC) is a chronic inflammatory disease of the large intestine, often associated with significant impacts on patients' quality of life and public health systems. ...

